Literature DB >> 12770866

Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.

Lingling Shen1, Jianhua Shen, Xiaomin Luo, Feng Cheng, Yechun Xu, Kaixian Chen, Edward Arnold, Jianping Ding, Hualiang Jiang.   

Abstract

HIV-1 reverse transcriptase (RT) is the primary target for anti-AIDS chemotherapy. Nonnucleoside RT inhibitors (NNRTIs) are very potent and most promising anti-AIDS drugs that specifically inhibit HIV-1 RT. The binding and unbinding processes of alpha-APA, an NNRTI, have been studied using nanosecond conventional molecular dynamics and steered molecular dynamics simulations. The simulation results show that the unbinding process of alpha-APA consists of three phases based on the position of alpha-APA in relation to the entrance of the binding pocket. When alpha-APA is bound in the binding pocket, the hydrophobic interactions between HIV-1 RT and alpha-APA dominate the binding; however, the hydrophilic interactions (both direct and water-bridged hydrogen bonds) also contribute to the stabilizing forces. Whereas Tyr-181 makes significant hydrophobic interactions with alpha-APA, Tyr-188 forms a strong hydrogen bond with the acylamino group (N14) of alpha-APA. These two residues have very flexible side chains and appear to act as two "flexible clamps" discouraging alpha-APA to dissociate from the binding pocket. At the pocket entrance, two relatively inflexible residues, Val-179 and Leu-100, gauge the openness of the entrance and form the bottleneck of the inhibitor-unbinding pathway. Two special water molecules at the pocket entrance appear to play important roles in inhibitor recognition of binding and unbinding. These water molecules form water bridges between the polar groups of the inhibitor and the residues around the entrance, and between the polar groups of the inhibitor themselves. The water-bridged interactions not only induce the inhibitor to adopt an energetically favorable conformation so the inhibitor can pass through the pocket entrance, but also stabilize the binding of the inhibitor in the pocket to prevent the inhibitor's dissociation. The complementary steered molecular dynamics and conventional molecular dynamics simulation results strongly support the hypothesis that NNRTIs inhibit HIV-1 RT polymerization activity by enlarging the DNA-binding cleft and restricting the flexibility and mobility of the p66 thumb subdomain that are believed to be essential during DNA translocation and polymerization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12770866      PMCID: PMC1302942          DOI: 10.1016/S0006-3495(03)75088-7

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  60 in total

Review 1.  New developments in anti-HIV chemotherapy.

Authors:  E De Clercq
Journal:  Curr Med Chem       Date:  2001-11       Impact factor: 4.530

Review 2.  Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.

Authors:  Giuseppe Campiani; Anna Ramunno; Giovanni Maga; Vito Nacci; Caterina Fattorusso; Bruno Catalanotti; Elena Morelli; Ettore Novellino
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

Review 3.  Advances in QSAR studies of HIV-1 reverse transcriptase inhibitors.

Authors:  Satya P Gupta
Journal:  Prog Drug Res       Date:  2002

4.  Atomic force microscope.

Authors: 
Journal:  Phys Rev Lett       Date:  1986-03-03       Impact factor: 9.161

5.  Comparison of three different crystal forms shows HIV-1 reverse transcriptase displays an internal swivel motion.

Authors:  J Jäger; S J Smerdon; J Wang; D C Boisvert; T A Steitz
Journal:  Structure       Date:  1994-09-15       Impact factor: 5.006

6.  Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; M J Camarasa; W G Tarpley; E De Clercq
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

9.  Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

Authors:  Y Hsiou; K Das; J Ding; A D Clark; J P Kleim; M Rösner; I Winkler; G Riess; S H Hughes; E Arnold
Journal:  J Mol Biol       Date:  1998-11-27       Impact factor: 5.469

Review 10.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

View more
  22 in total

Review 1.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

2.  Unbinding Dynamics of Non-Nucleoside Inhibitors from HIV-1 Reverse Transcriptase.

Authors:  Leela S Dodda; Julian Tirado-Rives; William L Jorgensen
Journal:  J Phys Chem B       Date:  2019-01-03       Impact factor: 2.991

3.  Solution characterization of [methyl-(13)C]methionine HIV-1 reverse transcriptase by NMR spectroscopy.

Authors:  Xunhai Zheng; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Antiviral Res       Date:  2009-08-07       Impact factor: 5.970

4.  Conformational Plasticity of the NNRTI-Binding Pocket in HIV-1 Reverse Transcriptase: A Fluorine Nuclear Magnetic Resonance Study.

Authors:  Naima G Sharaf; Rieko Ishima; Angela M Gronenborn
Journal:  Biochemistry       Date:  2016-07-11       Impact factor: 3.162

5.  Using steered molecular dynamics to study the interaction between ADP and the nucleotide-binding domain of yeast Hsp70 protein Ssa1.

Authors:  You-Lin Xue; Qiaoshi Zhang; Yuna Sun; Xiaohong Zhou; Ian P Hurley; Gary W Jones; Youtao Song
Journal:  J Comput Aided Mol Des       Date:  2018-11-03       Impact factor: 3.686

6.  A molecular dynamics study of the ligand release path in yeast cytosine deaminase.

Authors:  Lishan Yao; Honggao Yan; Robert I Cukier
Journal:  Biophys J       Date:  2007-01-11       Impact factor: 4.033

Review 7.  Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.

Authors:  Francesc Xavier Ruiz; Eddy Arnold
Journal:  Curr Opin Struct Biol       Date:  2020-01-11       Impact factor: 6.809

8.  Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding.

Authors:  James M Seckler; Mary D Barkley; Patrick L Wintrode
Journal:  Biophys J       Date:  2011-01-05       Impact factor: 4.033

9.  Molecular dynamics simulation and steered molecular dynamics simulation on irisin dimers.

Authors:  Qi Gao; Chao Lu; Xiao-Wen Wang; Jun-Wei Zhang; Youtao Song; You-Lin Xue
Journal:  J Mol Model       Date:  2018-03-16       Impact factor: 1.810

10.  Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures.

Authors:  Kristina A Paris; Omar Haq; Anthony K Felts; Kalyan Das; Eddy Arnold; Ronald M Levy
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.